ARTEMIS-IPF: A Phase 3, Randomized, Double Blind, Placebo Controlled, Multi Center, Parallel Group, Event Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPF

Gilead Sciences Incorporated0 个研究点目标入组 660 人开始时间: 2009年4月28日最近更新: 2012年4月18日

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 660

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1.Male or females from 40 to 80 years of age
•2.Diagnosis of Idiopathic Pulmonary Fibrosis (IPF) based on the following criteria in accordance with ATS-ERS guidelines for diagnosing IPF:
•—Definite or probable UIP confirmed on SLB by core pathologist
•—In absence of SLB, HRCT scan showing definite findings for IPF (bibasilar reticular abnormalities with minimal ground glass opacities) as determined by core review
•and three of the following minor criteria”:
•—Age > 50 years
•—Insidious onset of otherwise unexplained dyspnea on exertion
•—Duration of illness = 3 months
•—Bibasilar, inspiratory crackles
•Within 90 days of study enrollment, diagnosis must be confirmed by HRCT
•3.Honeycombing = 5% as assessed on HRCT; HRCT results will undergo a core review process (Section 7.4) to confirm diagnosis.
•4.Willingness to undergo RHC at baseline and at Visit 7 or end of study (EOS)
•5.Willingness and ability to comply with required monitoring of liver function every 28 days. LFTs include serum ALT, AST, alkaline phosphatase, gamma glutamyl transferase (GGT), and total bilirubin concentrations
•6.Forced vital capacity (FVC) > 50 to = 95% of predicted with a ratio of
•FEV1 (L) / FVC (L) = 0.7. Pulmonary function tests must be completed no more than 90 days before enrollment
•7.Ability to perform and complete 6MWT at screening
•8.Negative serum pregnancy test at screening and negative urine pregnancy test at randomization for female subjects of childbearing potential (defined in Section 6.3).
•9.Female subjects of childbearing potential must be willing to use at least two reliable methods of contraception throughout their participation in the study and 30 days after discontinuation of IMP unless the subject has had a tubal sterilization, is postmenopausal, or has a Copper T 380A intrauterine device (IUD) or LNg 20 IUD inserted, in which case no other contraception is needed. Subjects of childbearing potential must also be willing to undergo pregnancy tests every 28 days.
•10.Male subjects must be capable of understanding and acknowledging potential risks of testicular tubular atrophy and infertility associated with taking this IMP as described in the Informed Consent Form (ICF)
•11.Competency to understand the information given in the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approved ICF. Subjects must sign the form prior to the initiation of any study procedures, unless the assessment is performed in the routine care for this disease
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1.Diagnosis of an ILD or restrictive lung disease other than UIP or IPF
•2.Obstructive lung disease as determined by evidence of airflow obstruction on HRCT or physiologic criteria including:
•FEV1/FVC ratio < 0.7
•RV > 120% by plethysmography or significant (verified by radiologist) emphysema on HRCT if plethysmography not available
•Evidence of reactive airway disease by change in FEV1 of > 12% following bronchodilator challenge
•3.Evidence of sustained improvement of IPF condition defined as improvement from pre therapy PFTs observed with two or more successive post therapy PFTs over the year prior to randomization
•4.Condition(s) that is or are a contraindication for RHC including:
•Tricuspid or pulmonary valve stenosis
•Prosthetic tricuspid or pulmonary valve
•Right atrial or right ventricular masses
•Cyanotic heart disease
•Allergy to latex or catheter material
•Previous pneumonectomy.
•5.Active or recent (= 60 days prior to enrollment) pulmonary or upper respiratory tract infection
•6.Hospitalization within 60 days of screening for an acute exacerbation of IPF
•7.Chronic heart failure (NYHA class III/IV) or known left ventricular ejection fraction < 25%
•8.Chronic treatment with the following drugs prescribed for IPF (within 4 weeks of randomization):oral corticosteroids (> 20 mg/day of prednisone or equivalent), immunosuppressive or cytotoxic drugs, antifibrotic drugs, chronic use of N-acetylcysteine (prescribed for IPF)
•9.Acute or chronic impairment (other than dyspnea) which limits the ability to comply with study requirements and procedures including the 6MWT
•10.Treatment with ambrisentan in a clinical study or with commercial product
•11.Treatment with an approved or experimental ERA within 30 days prior to randomization
•12.Chronic use of sildenafil or other phosphodiesterase type 5 (PDE 5) inhibitor for pulmonary hypertension
•13.Chronic treatment with immunosuppressive, cytotoxic, or antifibrotic drugs including pirfenidone, D penicillamine, colchicine, TNF a antagonists, imatinib, interferon gamma, cyclophosphamide, cyclosporine A, or azathioprine within 30 days of randomization (Section 5.4)
•14.Prior ERA treatment discontinued for any toxicity
•15.ALT or AST > 1.5 × ULN at screening
•16.Hemoglobin concentration < 75% of LLN at screening
•17.Serum creatinine = 2.5 mg/dL (221 µmol/L) or subject requires hemodialysis, peritoneal dialysis or hemofiltration
•18.Systolic blood pressure < 85 mmHg
•19.History of malignancies within the past 5 years, with the exception of basal cell carcinoma of the skin or successfully treated in situ carcinoma of the cervix
•20.Female who is pregnant or nursing
•21.Known history of alcohol abuse within 1 year of enrollment
•22.Participation in a clinical study and receiving another investigational drug or device (not placebo) within 28 days of screening
•23.Comorbid condition or illness limiting life expectancy to < 1 year at time of screening
•24.Serious or active medical or psychiatric condition which, in the opinion of the Investigator, would interfere with subject treatment, assessment or compliance with the protocol

研究者

发起方

Gilead Sciences Incorporated

相似试验

进行中（未招募）

不适用

ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PHPulmonary Hypertension associated with Idiopathic Pulmonary FibrosisMedDRA version: 12.0Level: LLTClassification code 10021240Term: Idiopathic pulmonary fibrosisMedDRA version: 12.0Level: LLTClassification code 10037400Term: Pulmonary hypertension

EUCTR2009-011169-98-GBGilead Sciences, Inc225

进行中（未招募）

不适用

EUCTR2009-011169-98-ATGilead Sciences, Inc225

进行中（未招募）

不适用

EUCTR2009-011169-98-DEGilead Sciences, Inc225

进行中（未招募）

不适用

EUCTR2009-011169-98-CZGilead Sciences, Inc.225

进行中（未招募）

不适用

ARTEMIS: A Phase 3, Randomized, Double-Blind,Placebo-Controlled, Multi-Center, Parallel-Group,Event-Driven Study to Evaluate the Efficacy and Safety ofAmbrisentan in Subjects with Early Idiopathic PulmonaryFibrosis (IPF)ARTEMIS: Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, multicéntrico, con grupos paralelos, en función de eventos, para evaluar la eficacia y seguridad de ambrisentan en sujetos con fibrosis pulmonar idiopática temprana (FPI). - ARTEMIS

EUCTR2008-004405-34-ESGilead Sciences Incorporated600